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Abstract
Background: Histone deacetylases (HDACs) are enzymes that modulate gene expression and cellular processes by
deacetylating histones and non-histone proteins. While small molecule inhibitors of HDAC activity (HDACi) are used
clinically in the treatment of cancer, pre-clinical treatment models suggest they also exert neuroprotective effects
and stimulate neurogenesis in neuropathological conditions. However, the direct effects of HDACi on cell cycle
progression and proliferation, two properties required for continued neurogenesis, have not been fully
characterized in adult neural stem cells (NSCs). In this study, we examined the effects of two broad class I and class
II HDACi on adult mouse NSCs, the hydroxamate-based HDACi suberoylanilide hydroxamic acid (vorinostat, SAHA)
and the short chain fatty acid HDACi sodium butyrate.
Results: We show that both HDACi suppress the formation of neurospheres by adult mouse NSCs grown in
proliferation culture conditions in vitro. DNA synthesis is significantly inhibited in adult mouse NSCs exposed to
either SAHA or sodium butyrate and inhibition is associated with an arrest in the G1 phase of the cell cycle. HDACi
exposure also resulted in transcriptional changes in adult mouse NSCs. Cdk inhibitor genes p21 and p27 transcript
levels are increased and associated with elevated H3K9 acetylation levels at proximal promoter regions of p21 and
p27. mRNA levels for notch effector Hes genes and Spry-box stem cell transcription factors are downregulated,
whereas pro-neural transcription factors Neurog1 and Neurod1 are upregulated. Lastly, we show HDAC inhibition
under proliferation culture conditions leads to long-term changes in cell fate in adult mouse NSCs induced to
differentiate in vitro.
Conclusion: SAHA and sodium butyrate directly regulate cdk inhibitor transcription to control cell cycle
progression in adult mouse NSCs. HDAC inhibition results in G1 arrest in adult mouse NSCs and transcriptional
changes associated with activation of neuronal lineage commitment programs and a reduction of stem/progenitor
state. Changes in differentiated cell state in adult mouse NSCs treated with HDACi under proliferation culture
conditions suggests an intrinsic relationship between multipotency, cell cycle progression and HDAC activity in
these cells.
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Adult neural stem cell (NSC) maintenance and differen-
tiation is controlled by intrinsic and extrinsic factors.
Many developmental cues have been shown to operate
in the adult NSC niche including Wnt [1], sonic hedge-
hog [2,3], bone morphogenic protein [4] and notch sig-
naling [5,6]. More recently the modification of histone
proteins has been identified as an epigenetic regulator of
adult neurogenesis [7-9]. Gene expression is epigeneti-
cally regulated by enzymatic modifications of histone
proteins and changes in histone acetylation by the
opposing activities of histone acetyltransferases (HATs)
and histone deacetylases (HDACs) is considered the
more dynamic form of regulation. HDACs catalyze the
removal of an acetyl moiety from the ε-amino group of
target lysine residues in histone proteins (reviewed in
Grayson et al 2010) and histone deacetylation leads to a
condensed chromatin structure that is primarily asso-
ciated with the repression of transcription (it should be
noted HDACs deacetylate other non-histone proteins
such as a-tubulin and b-catenin, see [10]).
The ability to inhibit HDAC activity with small mole-
cule HDAC inhibitors (HDACi) has attracted consider-
able therapeutic attention. Initial interest focused on the
application of HDACi as anti-cancer agents and suber-
oylanilide hydroxamic acid (vorinostat, SAHA, Zolinza)
is the first HDACi approved by the FDA for cancer
therapy. More recently, therapeutic interest in HDACi
has broadened to non-malignant conditions effecting the
nervous system [11]. Pre-clinical treatment models
demonstrate HDACi exert neuroprotective effects and
stimulate neurogenesis in traumatic brain injury (TBI)
and ischemia [12,13], restore learning and memory in
TBI and neurodegenerative mice [14,15], enhance neu-
ronal differentiation and synaptic plasticity [16,17] and
exert antidepressant-like effects [18]. However these
same HDACi have also been reported to both prevent
[19] or induce neuronal apoptosis in culture [20,21], a
contradiction that is likely the result of differences in
neuronal cell type, the culture conditions employed and
the type of HDACi molecule tested.
In an effort to determine the cell specific effects of
HDACi on adult neurogenesis, we have investigated the
effects of the broad class I and class II HDAC inhibitors
SAHA (a hydroxamate-based HDACi) and sodium buty-
rate (a short chain fatty acid) on adult mouse NSC biol-
ogy in vitro. Our data indicate these two HDACi exert
similar anti-proliferative effects in vitro by blocking G1-
to-S phase progression in adult mouse NSCs. G1 arrest
is associated with the up-regulation of expression of
cyclin-dependant kinase (cdk) inhibitors, the down-regu-
lation of stem/progenitor transcription factors and up-
regulation of pro-neural transcription factors in adult
NSCs. Chromatin immunoprecipitation (ChIP) confirms
HDACi directly regulate cdk inhibitor expression in
adult mouse NSCs. Finally, we show HDACi treatment
under proliferation culture conditions leads to long-
term changes in cell fate in adult NSCs induced to dif-
ferentiate in vitro. Combined these data indicate an
intrinsic relationship between multipotency, cell cycle
progression and HDAC activity in adult mouse NSCs.
Results
SAHA and NaB inhibit neurosphere formation by adult
mouse NSCs in vitro
We have examined the effects of two HDAC inhibitors,
the hydroxamate-based HDAC inhibitor suberoylani-
lide hydroxamic acid (vorinostat, SAHA) and the short
chain fatty acid sodium butyrate (NaB). SAHA and
NaB are broad class I and class II HDAC inhibitors
effective in micromolar (μM) and millimolar (mM)
ranges respectively.
We examined the effects of 1 μMS A H Aa n d1m M
N a Bo na d u l tN S C sg r o w ni np r o l i f e r a t i o nc u l t u r e
conditions in vitro. Pharmacokinetics indicate 1 μM
SAHA treatment falls within the range of clinical use
for this compound (effective anti-tumor oral doses of
200-400 mg vorinostat produce peak serum concen-
trations of 1.1-1.2 μM, see [22]). Western blot analysis
of whole cell extracts from adult NSCs treated with
HDACi for 48 hours confirms SAHA and NaB treat-
m e n tr e s u l t si na ni n c r e a s ei nh i s t o n e3( H 3 )a c e t y l a -
tion levels when compared to DMSO and water
vehicle controls (Figure 1a).
HDACi treatment was associated with clear differ-
ences in adult NSC behavior in culture. HDACi-treated
adult NSCs exhibited a static behavior when grown in
proliferative conditions compared to vehicle-treated
controls and failed to produce neurospheres of any sig-
nificant size or density in cultures (Figure 1b). Quantita-
tive analysis of adult NSCs after 7-days HDACi
treatment confirms SAHA and NaB treatment dramati-
cally inhibits the formation of neurospheres (diameter ≥
50 μm) and increase the prevalence of small (≥4 cells,
diameter < 50 μm) cell clusters in culture (Figure 1c).
HDACi treatment resulted in minor cell death in culture
that was most apparent during the first 1-2 days of
treatment. However, quantitative analysis indicates these
toxicity effects were not large-scale - LIVE/DEAD stain-
ing and flow cytometry reveals SAHA and NaB exposure
results in a 10% reduction in cell viability compared to
vehicle controls after 48 hours treatment (Figure 1d), a
difference that is not statistically significant (NaB vs.
vehicle p = 0.10, SAHA vs. vehicle p = 0.12, t-tests, n =
3). Rather, the increased prevalence of small cell clusters
suggests HDACi treatment results in a modestly toxic
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NSCs in our proliferative culture conditions.
SAHA and NaB block G1- to-S cell cycle progression in
adult mouse NSCs in vitro
We quantified the effects of HDACi treatment on adult
mouse NSC proliferation in vitro by comparing the
levels of EdU (5-ethynyl-2’-deoxyuridine) incorporation
in proliferation culture conditions. EdU is a nucleoside
analog to thymidine and is incorporated into DNA dur-
ing active DNA synthesis. Adult NSCs treated with
SAHA or NaB were exposed to EdU (10 μM) overnight
(16 hours) following 48 hours HDACi treatment. Cell
viability was measured by LIVE/DEAD stain and EdU
incorporation compared in live cell gated populations.
Flow cytometry measurement of EdU incorporation
rates confirmed the addition of either SAHA or NaB
significantly inhibited DNA synthesis in adult mouse
NSCs in vitro (Figure 2a). SAHA treatment resulted in a
6.61-fold reduction (8.9 ± 1.2% versus DMSO vehicle
56.3 ± 7.0%, p < 0.01) and NaB a 5.26-fold reduction
(10.4 ± 5.2% versus water vehicle 54.5 ± 7.5%, p <
0.001) in EdU incorporation rates compared to vehicle
controls.
Flow cytometry measurement of relative DNA content
in combination with EdU incorporation was used to
estimate the effects of SAHA and NaB on cell cycle pro-
gression in live cells. We used the Dean-Jett-Fox model
(Flowjo software) to estimate percentage cell populations
in G1 phase and G2/M phase of the cell cycle. This ana-
lysis revealed equivalent cell cycle effects in NSCs trea-
ted with SAHA or NaB. SAHA or NaB treatment
significantly increased the percentage of cells in G1
phase of the cell cycle (SAHA 65.6 ± 2.8% versus 49.9 ±
2.2% DMSO, p < 0.05 and NaB 63.3 ± 6.0% versus 47.5
± 1.3% water vehicle, p < 0.05), as shown in Figure 2b.
Correspondingly, as shown in Figure 2c, SAHA or NaB
treatment significantly decreased the percentage of cells
in G2/M phase (SAHA 12.3 ± 4.5% versus 27.6 ± 2.4%
DMSO, p < 0.05 and NaB 7.7 ± 5.2% versus 24.8 ± 1.7%
water vehicle, p < 0.05). Combined these flow cytometry
data indicate that the suppression of NSC proliferation
by SAHA and NaB results in a G1-to-S phase block in
cell cycle progression.
Gene expression changes induced by SAHA and NaB
treatments vary in fold change but not directionality
Genome-wide expression screening indicates HDAC
inhibition is associated with expression changes in ≈ 2-
5% of the genome [23]. We measured mRNA levels of a
cohort of 18 genes implicated in cell cycle progression,
stem cell maintenance and NSC fate using qRT-PCR.
Figure 1 HDACi treatment results in increased histone H3
acetylation, reduced neurosphere formation and minimal
toxicity in adult mouse NSCs grown in proliferation conditions
in culture. (a) Western blot of whole cell extracts demonstrates
SAHA and NaB treatment result in increased levels of acetylated
histone H3 compared to vehicle controls. (b) Light micrographs of
HDACi/vehicle treated cultures illustrate the paucity of neurospheres
in HDACi-treated cultures. (c) Quantitative analysis confirms SAHA
and NaB inhibit the formation of neurospheres (diameter ≥ 50 μm)
and increase the prevalence of small cell clusters (≥ 4 cell, diameter
<5 0μm). (d) Flow cytometry using LIVE/DEAD cell stain confirms
SAHA and NaB are minimally toxic compared to vehicle controls (n
= 3). Scale bar = 100 μm.
Figure 2 SAHA and NaB inhibit adult mouse NSC proliferation
in culture and arrest cells in G1 phase of the cell cycle. (a) EdU
flow cytometry of live cell-gated adult mouse NSCs demonstrates
SAHA (**p < 0.01) and NaB (***p < 0.001) significantly inhibit DNA
synthesis. (b) Analysis of DNA content by flow cytometry reveals
significant accumulation of adult mouse NSCs in G1phase of the
cell cycle following SAHA (*p < 0.05) and NaB (*p < 0.05) treatment.
(c) Correspondingly the proportion of cells in G2/M phase is
significantly reduced following SAHA (*p < 0.05) and NaB (*p <
0.05) treatment. (d) Fluorescence micrographs of HDACi/vehicle
treated adult NSCs pulse-labeled with EdU for flow cytometry. Scale
bar = 50 μm. Statistical comparisons performed using one-way
ANOVA with post hoc Newman-Keuls multiple comparison tests.
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of NSCs in proliferation culture conditions with HDACi
or vehicle. Our analysis revealed widespread changes in
gene expression following HDACi exposure (Table1).
Eight out of 18 genes analyzed showed increased expres-
sion and 10 decreased expression when compared to
vehicle control. SAHA and NaB treatment induced
greater than 2 fold expression changes in a majority of
the genes tested (in both a positive (+) and negative (-)
direction from vehicle controls). Noticeably, the direc-
tionality (+/-) fold change of gene expression changes
was consistent between the two HDACi treatments
when compared to vehicle controls. We speculate this
reflects the similar treatment outcome, G1 arrest, of
SAHA and NaB exposure on adult NSCs.
Gene expression changes induced by SAHA and NaB are
consistent with G1 arrest, a reduction in stem/progenitor
state and activation of neuronal lineage commitment
programs
Gene expression changes in HDACi treated adult NSCs
are consistent with the inhibition of G1-to-S phase cell
cycle progression. SAHA and NaB treatment result in
increased transcription of cyclin dependant kinase inhi-
bitors p21, p27 and p57, and the down-regulation of
cyclin dependant kinases Cdk2 and Cdk4 (Table 1). Pro-
gression through G1 and S phase of the cell cycle is
dependent on Cdk2 and Cdk4 and the activity of these
proteins is inhibited by binding of Cdk inhibitors p21,
p27 and p57. We also examined genes with functions
associated with stem/progenitor or neuronal cell fate.
Our analysis revealed SAHA and NaB treatment results
in the down-regulation of transcription factors asso-
ciated with the maintenance of a stem/progenitor cell
state and up-regulation of pro-neural transcription fac-
tors (Table 1). The progenitor cell cycle regulator c-Myc
and stem cell maintaining SRY-box factors are downre-
gulated by SAHA and NaB treatment, as are Notch
effector bHLH transcription factors Hes1 and Hes5
(Table 1). In contrast, mRNA levels of pro-neural bHLH
transcription factors reveal variable HDACi effects on
neuronal lineage commitment genes. Neurog1 and Neu-
rod1 are upregulated whereas Ascl1 is downregulated in
adult NSCs treated with SAHA or NaB (Table 1). In
summary, qRT-PCR expression data from our gene
cohort are consistent with G1 arrest accompanied by a
Table 1 Gene expression changes induced by SAHA or NaB treatment vary in fold change but not (+/-) directionality
and are consistent with G1 arrest, suppression of stem/progenitor and activation of neuronal lineage commitment
programs
Genes Upregulated compared to vehicle control
Gene Symbol Name SAHA NaB
Ctnnb1 Catenin, beta-1 1.31 ± 0.02 1.82 ± 0.34
Gli1 glioma-associated oncogene 5.26 ± 1.90 4.19 ± 2.77
Neurod1 Neurogenic differentiation1 4.28 ± 1.78 1.45 ± 0.60
Neurog1 Neurogenin 1 9.86 ± 4.35 2.79 ± 1.38
Tcf4 Transcription factor 4 1.50 ± 0.34 1.09 ± 0.18
p21 (Cdkn1a) Cyclin-dependant kinase inhibitor 1a 5.48 ± 2.98 3.35 ± 0.99
p27 (Cdkn1b) Cyclin-dependant kinase inhibitor 1b 2.70 ± 0.64 2.34 ± 0.31
p57 (Cdkn1c) Cyclin-dependant kinase inhibitor 1c 1.89 ± 0.48 3.33 ± 1.17
Shh Sonic hedgehog 41.57 ± 6.98 6.31 ± 2.37
Genes Downregulated compared to vehicle control
Gene Symbol Name SAHA NaB
Ascl1 Achaete-scute complex homolog 1 -2.36 ± 0.71 -3.43 ± 0.92
Cdk2 Cyclin-dependant kinase 2 -4.64 ± 1.91 -8.37 ± 5.87
Cdk4 Cyclin-dependant kinase 4 -3.35 ± 0.70 -4.18 ± 0.17
Ccnd1 Cyclin D1 -1.55 ± 0.63 -1.87 ± 0.17
Hes1 Hairy/enhancer of split, Drosophila homolog of, 1 -3.89 ± 1.90 -5.56 ± 0.57
Hes5 Hairy/enhancer of split, Drosophila homolog of, 1 -11.87 ± 1.18 -23.85 ± 3.15
c-Myc V-myc avian myelocytomatosis viral oncogene homolog -1.92 ± 0.77 -2.44 ± 1.05
Olig2 Oligodendrocyte lineage transcription factor 2 -1.06 ± 0.03 -2.83 ± 1.71
Pax6 Paired box gene 6 -2.04 ± 1.18 -4.22 ± 1.92
Sox1 SRY-box 1 -4.46 ± 3.33 -4.96 ± 2.52
Sox2 SRY-box 2 -3.08 ± 1.60 -3.44 ± 1.06
Sox9 SRY-box 9 -2.35 ± 0.25 -1.24 ± 1.06
+/- fold-changes in gene expression in adult mouse NSCs treated with SAHA or NaB were calculated from vehicle controls from ≥ 3 independent qRT-PCR trials
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Neurog1/Neurod1 neuronal lineage commitment
programs.
Increased transcription of Cdk inhibitors is associated
with increased histone acetylation at the proximal
promoter in HDACi treated adult mouse NSCs
Transcription of the cell cycle regulator p21 is directly
regulated by HDAC1 and HDAC2 [24-27] and is re-acti-
vated by HDAC inhibitors in tumor cells [28]. To test
whether HDAC inhibitor treatment increased histone
acetylation levels at the proximal promoter of the p21
gene (Cdkn1a) in adults NSCs, we performed chromatin
immunoprecipitation (ChIP) using antibodies to acety-
lated lysine 9 on histone H3 (anti-H3acK9). qPCR analy-
sis reveals SAHA induces a 7.2-fold increase and NaB a
3.1-fold increase in H3K9 acetylation levels at the p21
promoter compared to DMSO and water vehicle con-
trols respectively (Figure 3a). Statistical analysis confirms
a significant increase in H3K9 acetylation in adult NSCs
in response to SAHA (p < 0.01) and NaB (p < 0.05), as
well as significant interaction between the immunopreci-
pitation (IP) antisera (p < 0.0001) and treatment (p <
0.05). We also analyzed H3K9 acetylation levels at the
proximal promoter of p27 (Cdkn1b). Expression of p27
is increased in some but not all tumor cells by HDACi
and is upregulated in human mesenchymal stem cells by
SAHA treatment [29]. As shown in figure 3b, ChIP
revealed a 2-fold increase H3K9 acetylation levels at the
p27 promoter in response to SAHA treatment that was
statistically significant (p < 0.05). In contrast, no
increase in H3K9 acetylation was observed at the p27
promoter in response to NaB treatment (Figure 3b).
Combined these data indicate transcriptional activation
of p21 and p27 by SAHA is associated with increased
H3K9 acetylation at proximal promoter regions, suggest-
ing direct activation of these gene targets. Increased p21
expression and increased in H3K9 acetylation at the p21
promoter in NaB treated cells suggests NaB similarly
directly activates p21 transcription in adult NSCs. In
contrast, the absence of significant changes in H3K9
acetylation at the p27 promoter suggests the involve-
ment of alternative mechanisms, possibly acetylation of
non-histone proteins, in NaB-mediated increases in p27
expression in adult NSCs.
Treatment of proliferating adult mouse NSCs with HDACi
leads to changes in differentiated cell fate
Inhibition of histone deacetylases promotes the acquisi-
tion of neuronal and suppresses glial cell fates in differ-
entiating adult NSCs [17,30]. Based on these
observations, we predicted HDACi treatment of prolifer-
ating adult mouse NSCs would lead to changes in cell
fate in adult NSCs induced to differentiate in culture.
To test this hypothesis, we developed a 96-well plate
immunofluorescence cell fate assay using antibodies to
GFAP, Olig2 and NeuN as general markers of astrocytic,
oligodendrocyte and neuronal cell fates. Adult NSCs
were first treated with HDACi for 48 hours under pro-
liferation culture conditions and then cultured for 14
days under differentiation conditions without HDACi.
These assays revealed SAHA significantly reduced glial
(p < 0.001) and oligodendrocyte (p < 0.05) differentiated
cell fate in culture when compared to DMSO vehicle
controls (Figure 4a). However NeuN immunoassays
indicate this did not lead to a compensatory increase in
neuronal cell fate (Figure 4a). Although NaB treatment
similarly reduces the expression of glial and oligoden-
drocyte cell markers, these differences were not
Figure 3 Upregulated p21 and p27 expression in adult mouse
NSCs treated with HDACi is associated with increased
acetylation at the proximal promoter. (a) Chromatin
immunoprecipitation (ChIP) reveals significant increases in histone
H3 lysine 9 acetylation levels at the proximal promoter of p21 in
SAHA (***p < 0.001) and NaB (*p < 0.05) treated adult mouse NSCs.
(b) ChIP reveals significant increases in histone H3 lysine 9
acetylation levels at the proximal promoter of p27 in SAHA (**p <
0.01) but not NaB treated adult mouse NSCs. Statistical comparisons
performed using two-way ANOVA with Bonferroni post-tests.
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case with SAHA, NaB treatment did not alter NeuN
expression levels (Figure 4a).
In an effort to identify molecular mechanisms respon-
sible for SAHA-induced suppression of oligodendrocyte
cell fate, we measured b-catenin protein levels in
HDACi-treated adult NSCs by Western blot. Combined
deletion of Hdac1 and Hdac2 in mice is reported to
inhibit oligodendrocyte differentiation through the stabi-
lization and nuclear translocation of b-catenin, which in
turn represses Olig2 expression [31]. Hence our ratio-
nale was that SAHA inhibits Hdac1/2 in proliferating
adult NSCs leading to increased nuclear localization of
b-catenin and longer-term suppression of oligodendro-
cyte fates. However, Western blots (n = 4) of adult
NSCs treated with HDACi under proliferation condi-
tions do not reveal significant changes in b-catenin
nuclear localization in treated cells (Figure 4b and 4c).
Fold-changes of b-catenin nuclear protein levels normal-
ized to laminin A/C reveal marginal opposing +/- effects
of SAHA (-1.49 ± 0.11) and NaB (1.36 ± 0.33) treat-
ment, indicating SAHA modulates cell fate via mechan-
isms independent of increased b-catenin stabilization.
Discussion
In this study we demonstrate the broad class I and class
II histone deacetylase inhibitors SAHA and NaB block
adult NSC proliferation in vitro by blocking G1-to-S
progression. HDACi induced cell cycle blockade is
accompanied by transcriptional changes consistent with
G1 arrest, a reduction of stem/progenitor cell state and
activation of neuronal lineage commitment programs in
adult NSCs. Furthermore, HDACi treatment of adult
NSCs in proliferation culture conditions leads to longer-
term changes in cell fate when cells are induced to dif-
ferentiate in culture.
SAHA and NaB block G1-to-S cell cycle progression in
adult NSCs and activate cdk inhibitor expression
We have shown SAHA and NaB treatment inhibits adult
NSC proliferation in vitro by arresting cells in G1 phase
of the cell cycle. G1 arrest induced by SAHA or NaB
treatment has been reported in fibroblasts [32], vascular
smooth muscle cells [33] and numerous tumor cell
types (see [28]). In many of these contexts, G1 arrest is
associated with increased expression of p21 [34] indicat-
ing the anti-proliferative effects of SAHA and NaB are,
in part, mediated by changes in the expression of cyclin
dependant kinase inhibitors.
The functional link between HDAC-mediated regula-
tion of cyclin dependant kinase inhibitor activity and
cell cycle progression is supported by a number of
genetic studies targeting HDAC genes in mice. Targeted
deletion of Hdac1 in mice results in embryonic lethality
associated with severe reductions in embryonic stem cell
proliferation and increased p21 and p27 expression in
null mutant embryos [27]. Furthermore, disruption of
the p21 gene (Cdkn1a) rescues the proliferation pheno-
type of Hdac1-/- mouse embryonic stem cells (but not
Figure 4 HDACi treatment under proliferation culture
conditions leads to long-term changes in differentiated cell
fate. (a) Immunofluorescence labeling of NeuN, GFAP and Olig2 cell
fate markers reveals reduced expression of GFAP (*p < 0.001) and
Olig2 (*p < 0.05) in adult mouse NSCs treated with SAHA for 48
hours under proliferation culture conditions and then induced to
differentiate for 14 days in culture (two-way ANOVA with Bonferroni
post-tests). (b) Western blot of b-catenin protein in nuclear and
cytoplasmic fractions of adult mouse NSCs treated with HDACi/
vehicle control under proliferation culture conditions. Gapdh and
lamin A/C blots are included as loading controls. (c) SAHA and NaB
do not significantly alter nuclear/cytoplasmic levels of b-catenin in
adult mouse NSCs. Histogram of b-catenin Western blot signal
intensities normalized to loading controls (n = 4).
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immunoprecipitations confirm the presence of HDAC1
at the p21 promoter [26]. Similarly, combined deletion
of HDAC1 and HDAC2 in primary fibroblasts and B-
cells results in a strong G1 cell cycle block that is
accompanied by increased p21 and p57 transcription
[25], and loss of HDAC1/2 catalytic activity results in
G1 arrest and up-regulation of p21 in primary and
oncogenic-transformed embryonic fibroblasts [24].
Taken together these studies indicate HDAC1 and
HDAC2 regulate G1-to-S cell cycle progression in mul-
tiple cell types by normally repressing the expression of
cyclin dependant kinase inhibitor genes, in particular
through transcriptional repression of p21.
In agreement with this, our data reveal SAHA and NaB
upregulated p21 mRNA expression in adult mouse NSCs
and that transcriptional activation is associated with
increased H3K9 acetylation at the proximal promoter
region of the p21 gene. This data indicates SAHA and
NaB directly increases the acetylation of associated chro-
matin histone residues to upregulate p21 transcription in
adult NSCs in vitro, a finding that implies class I and/or
class II HDAC activity directly represses p21 gene tran-
scription in adult NSCs to regulate cell proliferation.
Similarly our data demonstrates SAHA and NaB upregu-
lated p27 mRNA expression in adult NSCs. However,
p27 transcriptional activation is associated with increased
H3K9 acetylation at the gene’s proximal promoter region
of SAHA but not NaB treated adult NSCs. This suggests
HDAC activity inhibited by SAHA but not NaB directly
represses p27 transcription in adult NSCs to regulate cell
proliferation. The fact that p27 mRNA levels are upregu-
lated by NaB treatment irrespective of H3K9 acetylation
c h a n g e ss u g g e s t si n d i r e c tN a Be f f e c t so np 2 7t r a n s c r i p -
tion in adult NSCs. We speculate that one of the various
acetylated non-histone proteins such as p53 may provide
the linkage between HDACi and p27 repression [34,35].
SAHA and NaB treatment suppresses stem/progenitor
and activates neuronal lineage commitment programs in
adult NSCs
Our expression data demonstrates SAHA and NaB
treatment results in significant changes in gene tran-
scription, changes that differed in magnitude but not
directionality from vehicle controls reflecting the similar
treatment outcomes of the two HDACi. The three sig-
naling pathways represented within our gene cohort,
Sonic Hedgehog [2,36], Wnt/b-catenin [1] and Notch
[37] signaling are known to combine to regulate NSC
proliferation and neurogenesis in adult rodents. Thus
the widespread changes in gene expression indicate
HDAC inhibitors alter the output of each of the major
regulatory pathways identified in adult NSCs. And since
these pathways also control subsequent cell fate
selection, it was not surprising that we observed altera-
tions in cell markers such as Olig2 when cells were
induced to differentiate.
Overall, the expression data demonstrated HDACi
treatment downregulates transcription factors implicated
in the maintenance of stem/progenitor cell states and
upregulates transcription factors that drive neuronal
lineage commitment and differentiation. However, there
are a few exceptions that merit discussion. These are
the downregulation of pro-neural bHLH factor Ascl1
and the upregulation of Shh and Gli1 mRNAs. Ascl1
downregulation could result indirectly through the mod-
ulation of upstream activators such as Tlx [38]. ChIP
data suggests direct HDACi effects at the Shh loci
account for the increase in transcription of Shh and its
target Gli1 (data not shown). The fact that Shh-Gli1
upregulation is accompanied by G1 arrest in our study
suggests the mitogenic effects of Shh in adult NSCs [3]
require normal HDAC function.
In addition to activating cell lineage commitment pro-
grams [28,39], HDACi also promote the re-setting of
multipotency in terminally differentiated cell lineages by
increasing induced pluripotent stem cell (iPS) re-pro-
gramming efficiency [40-42]. Somatic cell re-program-
ming reactivates expression of Nanog, a homeobox
transcription factor necessary for maintaining multipo-
tency in embryonic stem (ES) cells [43]. In ES cells,
mSin3A-HDAC complex at the Nanog promoter acts to
positively regulate Nanog expression under proliferating
conditions and HDAC inhibition by TSA downregulates
Nanog expression [44], a finding that is analogous to
SAHA and NaB repression of multipotent factors in our
adult mouse NSC cultures.
In our study both SAHA and NaB downregulate the
expression of the stem cell maintaining factor Sox2 in
adult mouse NSCs. Conditional gene deletion in mice
reveals Sox2 is negatively regulated by Hdac2 in adult
neuroblasts and that Sox2 repression is necessary for
adult neurogenesis - Hdac2-/- neuroblasts ectopically
maintain Sox2 expression, fail to mature into neurons
and ultimately die of apoptosis [8]. Taking our data into
consideration, HDAC regulation of Sox2 expression in
adult NSC lineage progression appears to be biphasic: in
the first phase, class I and/or class II HDAC activity is
required to maintain Sox2 expression and the mainte-
nance of stem/progenitor programs in self-renewing
NSCs; in the second phase, HDAC2 functions to down-
regulate Sox2 in neuroblasts and permit the full activa-
tion of neuronal differentiation programs.
SAHA treatment leads to cell fate changes in
differentiated adult NSCs
Our cell fate analysis revealed SAHA treatment of
adult NSCs under proliferation culture conditions lead
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cyte cell fate markers GFAP and Olig2 in cells induced
to differentiate. Using Olig1-Cre and floxed Hdac1 and
Hdac2 mice, Ye et al. (2009) showed combined dele-
tion of Hdac1 and Hdac2 in oligodendrocyte progeni-
tor cells inhibited oligodendrocyte differentiation by
repressing Olig2 expression. This effect was mediated
by the stabilization (reduced phosphorylation) and
nuclear translocation of b-catenin, which in turn nega-
tively regulates oligodendrocyte development by
repressing Olig2 expression [31]. These authors identi-
fied the transcription factor TCF7L2/TCF4 as a co-
effector with b-catenin in the regulation of oligoden-
drocyte differentiation and speculate HDAC1/2 compe-
tition with b-catenin for TCF7L2 interaction converts
TCF7L2 from a repressor to an activator of oligoden-
drocyte differentiation. Accordingly, we hypothesized
HDACi induced increases in b-catenin stabilization
and nuclear localization accounted for Olig2 suppres-
sion in our cell fate assays. However Western blot ana-
lysis failed to detect significant differences in nuclear
protein levels of b-catenin in adult mouse NSCs trea-
ted with HDACi under proliferation culture conditions.
We speculate HDACi effects on other targets offset
this competitive interaction. One possible candidate is
Hdac6, a class IIb HDAC. Hdac6 deacetylates b-cate-
nin at lysine 49 (Lys49) to reduce b-catenin phosphor-
ylation and promote b-catenin nuclear localization and
c-myc induction [45]. Thus inhibition of Hdac1/2 and
Hdac6 activity has the capacity to promote opposing
effects on b-catenin stability and nuclear localization
by increasing stability (and reducing phosphorylation)
via inhibition of Hdac1/2 as well as decreasing stability
and nuclear localization as a result of increased Lys49
acetylation and phosphorylation. Indeed differential
sensitivities of Hdac1/2 and Hdac6 to SAHA and NaB
inhibition might underlie the different +/- fold-changes
in b-catenin nuclear localization compared to vehicle
controls). The fact that the effects of HDACi are con-
sistent with anti-proliferative responses to pharmacolo-
gical and genetic interventions targeting the canonical
Wnt/b-catenin signaling pathway in adult NSCs [1,46]
suggests the net effect of these molecules is to inhibit
rather than activate this signaling pathway.
Conclusion
In summary, the broad class I and class II HDAC inhi-
bitors SAHA and NaB blocked G1-to-S phase progres-
sion in proliferating adult NSCs in vitro.G e n e
expression changes induced by SAHA and NaB treat-
ment in adult NSCs vary in fold change but not direc-
tionality, consistent with the comparable treatment
outcomes of G1 arrest. In addition, the +/- direction of
gene changes induced by SAHA and NaB treatment is
consistent with G1 arrest accompanied by a reduction
of stem/progenitor state and activation of neuronal
lineage commitment programs. SAHA and NaB treat-
ment induces increases in the transcription of Cdk
inhibitors p21 and p27 in adult NSCs which was asso-
ciated with elevated H3K9 acetylation levels at proxi-
mal promoter regions. This association is consistent
with direct SAHA and NaB effects on cell cycle arrest
genes in adult NSCs, in common with widely reported
HDACi induced growth arrest in normal and trans-
formed cells [28,47]. Finally, we show HDACi treat-
ment under proliferation culture conditions leads to
long-term changes in cell fate in adult NSCs induced
to differentiate in vitro.
Methods
Animals
8-10 week old male and female (equal numbers) C57BL/
6J mice were purchased from The Jackson Laboratory
and housed in the Uniformed Services University’sC e n -
ter for Laboratory Animal Medicine prior to experimen-
tal use. Animals were handled in accordance with
procedures approved by the Uniformed Services Univer-
sity of the Health Sciences Institutional Animal Care
and Use Committee (IACUC). All research complied
with DoD regulations as published in DoD Directive
3216.1. The University’s Center for Laboratory Animal
Medicine is a fully accredited institution with the Asso-
ciation for Assessment and Accreditation of Laboratory
Animal Care (AAALAC).
Neural stem cell culture
Adult neural stem cells (NSCs) were harvested from
t h es u b v e n t r i c u l a rz o n e( S V Z )o fa d u l tC 5 7 B L / 6 Jm i c e
for culture. Mice were deeply anesthetized with vapor-
ized isoflurane, decapitated, the whole brain dissected
out and the forebrain cut in serial, coronal sections 1
mm thick using a Sorvall Tissue Chopper. The SVZ
was dissected out from coronal sections and disso-
ciated to a single cell suspension using Neural Tissue
Dissociation kit (Mitenyi Biotech) according to the
manufacturer’s protocol. Cells were seeded at a cell
d e n s i t yo f1×1 0
5 cells/ml in mouse NeuroCult
® NSC
Basal Medium supplemented with mouse NeuroCult
®
NSC Proliferation Supplement, 20 ng/ml rh EGF, 10
ng/ml of rh FGF-b and 2 ug/ml Heparin (all StemCell
Technologies, Vancouver, BC, Canada). Cells were cul-
tured at 37°C, 5% CO2 and cultures passaged every 5-7
days. Cells were passaged a minimum of 5 times prior
to experimental analysis to ensure a high enrichment
of multipotent stem cells. Cells were dissociated to a
single cell suspension in 0.025% Trypsin-EDTA (Invi-
trogen, Carlsbad, CA, USA) and re-seeded in culture
medium at 1 × 10
5 cells/ml.
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HDAC inhibitors (HDACi) suberoylanilide hydroxa-
mic acid (SAHA, Selleck chemicals, Houston, TX,
USA) or sodium butyrate (NaB, Sigma, St. Louis, MO,
USA) were added to NSC cultures 2 hours post-pas-
s a g e .S A H Ao rN a Bw e r ea d d e dt oaf i n a lc o n c e n t r a -
tion in culture media of 1 μM or 1 mM respectively
from freshly prepared solutions of 100 μM SAHA/
DMSO and 100 mM NaB/water. An equal volume of
DMSO or water was added to cultures as vehicle
controls.
Small cell cluster and neurosphere counts
Following 7 days HDACi treatment, adult NSCs were
incubated with a 0.2% solution of trypan-blue dye and
small cell clusters/neurospheres excluding dye counted.
Average small cell clusters/neurospheres were estimated
from 10 randomly selected 2.1025 mm
2 counting areas
using an optical graticule and Zeiss inverted A1 micro-
scope. The criteria for inclusion as small cell clusters
were clusters of ≥ 4 cells but a cell aggregate sphere dia-
meter of < 50 μm. The criteria for neurospheres was a
cell aggregate sphere of ≥ 50 μm in diameter. Small cell
cluster/neurosphere numbers were compared to values
obtained from simultaneous vehicle control cultures to
calculate fold-changes. Counting area selection and cell
counting were independently performed by two
“blinded” investigators.
Flow Cytometry, Click-iT™ 5-ethynyl-2’-deoxyuridine
(EdU) and CellCycle DNA labeling
All procedures were performed according to the manu-
facturer’s instructions (Invitrogen). Adult NSCs cultures
were pulsed with 10 μM 5-ethynyl-2’-deoxyuridine
(EdU) in cell culture media for 4 or 16 hours at 37°C,
5% CO2, the cells harvested and labeled with Alexa
Fluor
® 488 dye by Click-iT™ chemistry. For combined
cell cycle analysis, cells were co-labeled with CellCycle
488-red (7-AAD) and LIVE/DEAD
® Fixable Violet
stains. For cells quantified for EdU content only, cells
were co-labeled with LIVE/DEAD
® Fixable Red stain
(Invitrogen).
DNA content and proliferation status data acquisition
was performed on a LRS II Flow Cytometer System at
low flowrate with standard compensation and double
discrimination parameters. Acquired data was analyzed
using FlowJo 9.0.1 (Ashland, OR, USA). Briefly, events
were first gated based on FSC and SSC parameters for
the prominent cell population, then gated based on
LIVE/DEAD signal. Live cells were analyzed for EdU
incorporation for proliferation and also DNA content.
Cell cycle analysis of the live population was performed
in FlowJo using a Dean-Jeff-Fox model to compute the
percentage of events in each phase.
Real-time quantitative reverse transcription PCR (qRT-
PCR)
First-strand cDNA was synthesized from 1 ug of total
RNA using random primer/oligo(dT) primer according
to the manufacturer’si n s t r u c t i o n s( A B I ,C a r l s b a d ,C A ,
USA). Synthesized cDNA was diluted to final concentra-
tion of 10 ng/ul for qPCR using SYBR Green Master
Mix (ABI) on an ABI 7500 Real-Time PCR System.
Optimum primers were designed using NCBI’sP r i m e r
BLAST http://www.ncbi.nlm.nih.gov/tools/primer-blast/.
Primer sequence pairs used are listed in table 2. Primer
specificity was confirmed by verifying a single PCR pro-
duct had been generated using UV gel electrophoresis,
as well as by confirming the melting temperature of the
product had a single value on dissociation plots. Gene
of interest (GOI) Ct values were normalized to internal
control 18S, Actb and/or Hprt1 to calculate ΔCt. Fold-
changes (F) in gene of interest (GOI) expression were
estimated using the ΔΔCt method: F = 2
-ΔΔCt where
ΔΔCt =G O IΔCt HDACi - GOI ΔCt vehicle control. Ct
values were measured in triplicate and recorded if the
standard deviation was < 0.3. All values represent a
minimum of 3 biological replicates.
Chromatin Immunoprecipitation (ChIP)
Adult NSCs were treated for 10 minutes with 1% for-
maldehyde in PBS at room temperature. The cells were
lysed in cell lysis buffer (5 mM PIPES (pH = 8.0), 85
mM KCl, 0.5% NP-40 and 1× protease Inhibitors, Pierce,
Rockford, IL, USA) and the crude cell lysate transferred
to a sonication buffer (1× PBS, 1% NP-40, 0.5% sodium
deoxycholate and 1× protease Inhibitors, Pierce). The
lysate was sonicated under conditions yielding fragments
ranging from 500 to 1,000 bp. Samples were subse-
quently precleared at 4°C with recombinant protein G
agarose beads (Roche, Indianapolis, IN, USA). Precleared
lysate (100 μl) diluted in immunoprecipitation buffer
(0.01% SDS/1.1% Triton X-100/1.2 mM EDTA/16.7 mM
Tris·HCl, pH 8.0/167 mM NaCl) was used for a 16 hour
overnight immunoprecipitation with 5 μgr a b b i ta n t i -
Histone H3 (acetyl K9) antibody or ChIP rabbit IgG
control (both Abcam) at 4°C. Immunoprecipitated com-
plexes were collected by incubation with recombinant
protein G agarose beads (Roche) for 1-4 hours at 4°C.
After washing and elution, formaldehyde cross-linking
was reversed with a 16 hour overnight incubation at 65°
C. Samples were purified using PCR purification kit col-
umns (Qiagen, Valencia, CA, USA) and used as a tem-
plate for qPCR.
Enrichment relative to input was calculated from
qPCR values from ChIP templates as follows. Standard
curves were generated from serial 10-fold dilutions of
10% of input DNA and plotted on a log10 scale to
obtain the linear relationship between Ct value and
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values were normalized to input and enrichment com-
pared to IgG control samples and differences statistically
determined (2-way ANOVA with Bonferroni post-tests).
p21 (Cip1/Waf1/Cdkn1a) primers used were GGGT
GCAGGGCTGGCTGAAC and TGGACATGGTGC
CTGTGGCT, p27 (Kip1/Cdkn1b) primers were CCCA-
GACCTGCGCGCTACTG and GACCACCGCCTC
GCCTCTCT.
Immunofluorescence Cell Fate Quantification
Passaged adult NSCs were seeded at 2,000 cells/well in
ploy-D-lysine coated black frame/white wall 96-well tis-
sue culture plates (Perkin Elmer, Waltham, MA, USA)
in NeuroCult
® NSC Basal Medium supplemented with
mouse NeuroCult
® NSC Proliferation Supplement, 20
ng/ml rh EGF, 10 ng/ml of rh FGF-b, 2 ug/ml Heparin
(all and SAHA or NAB added to culture medium as
described previously. In each 96-well plate, SAHA, NaB,
DMSO or water vehicle was added to equal numbers of
culture wells. After 48 hours medium was replaced with
NeuroCult
® NSC Basal Medium supplemented with
mouse NeuroCult
® NSC Differentiation Supplement.
Medium was refreshed after 7 days and cells grown for
a total of 14 days in culture before fixation in 4% paraf-
ormaldheyde in 1× PBS. Plates were washed in 1× PBS
and incubated with primary antibody at 4°C overnight.
Each plate was incubated with a single primary antibody
diluted in 1× PBS containing 1% NGS, 0.2% Triton X-
100. The primary antibodies and dilutions used were as
follows: 1: 500 dilution of mouse monoclonal anti-NeuN
(Millipore, Billerica, MA, USA); 1:2,000 dilution of
mouse monoclonal anti-GFAP (Abcam, Cambridge, MA,
USA); 1: 1,000 dilution of rabbit polyclonal anti-Olig2
(Millipore). The following day plates were washed in 1×
PBS and incubated with Alexa Fluor
® 488 conjugated
goat ant-mouse IgG or Alexa Fluor
® 555 conjugated
goat anti-rabbit IgG secondary antibodies (Invitrogen) at
1:1,000 dilution in 1× PBS for 60 minutes at room
temp. Plates were then washed in 1× PBS and the fluor-
escence signal in each well measured using a FLUOStar
Optima microplate reader (BMG FLUOStar, Cary, NC,
USA). The average fluorescence value for each treat-
ment was calculated and data obtained from 6 indepen-
dent replicates.
Western blot
Nuclear and cytoplasmic proteins were isolated from
adult NSCs using NE-PER
® reagents (Thermo Scientific)
according to the manufacturer’s instructions (Thermo
Scientific, Rockford, IL, USA). Protein fractions were
stored at -20°C in 1x Halt™ Protease Inhibitor Cocktail
(Thermo Scientific) until use. Protein extracts were
mixed with reducing sample buffer, separated by SDS-
PAGE and electro-transferred to PVDF membrane. 20
μg protein was loaded per lane. All washes and antisera
incubations were performed in 5% skim milk in TBS
with 0.1% Tween-20. Blots were incubated with primary
Table 2 Primer pairs used for qRT-PCR expression analysis





p21 (Cdkn1a) TCCAGGAGGCCCGAGAACGG CTCCGAACGCGCTCCCAGAC
p27 (Cdkn1b) GCACTGTGGAGCAGACGCCC TCTGCCAGCAGTCCTGGGGT
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antisera and dilutions used were as follows: 1: 2,000
mouse anti-b-catenin (BD Biosciences, Franklin Lakes,
NJ, USA); 1: 1,000 mouse anti-Gapdh (Millipore): 1,000
mouse anti-Laminin A/C (BD Biosciences). The follow-
ing day blots were washed 3 times and incubated with a
1:5,000 dilution of peroxidase-conjugated goat anti-
mouse IgG secondary antisera (Cell Signaling Technolo-
gies) for 1 hour at room temp. Blots were developed in
Immobilon chemiluminescent ECL substrate (Millipore)
for 5 minutes at room temp and the fluorescent signal
captured using a Fujifilm LAS-3000 phospho-imager
(Fujifilm, Valhalla, NY, USA). Immunosignal intensities
(protein density) were measured using Fujifilm Multi
Gauge software. Images were optimized for brightness
and contrast for publication.
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